Impact of dexmedetomidine in conjunction with a weaning protocol on post‐surgical opioid use in a neonatal intensive care unit

Abstract

AbstractStudy ObjectiveTo describe the impact of protocol‐driven dexmedetomidine (and clonidine) use on opioid exposure in post‐surgical neonates.DesignRetrospective chart review.SettingA Level III, surgical NICU.PatientsSurgical neonates who received clonidine or dexmedetomidine concomitantly with an opioid for sedation and/or analgesia post‐operatively.InterventionImplementation of a standardized sedation/analgesia weaning protocol.Measurements and Main ResultsThere were clinically, although not statistically, significant reductions in opioid wean duration (240 vs. 227 h, p = 0.82), total opioid duration (604 vs. 435 h, p = 0.23), and total opioid exposure (91 vs. 51 mg ME/kg, p = 0.13), and limited impact on NICU outcomes or pain/withdrawal scores with use of the protocol. Increases in use of medications in alignment with the protocol (e.g., scheduled acetaminophen and opioids weaned first) were noted.ConclusionsWe have been unable to demonstrate a reduction in opioid exposure with use of alpha‐2 agonists alone; addition of a weaning protocol showed a reduction in opioid duration and exposure (although not statistically significant). At this point, dexmedetomidine and clonidine should not be introduced outside standardized protocols with scheduled acetaminophen post‐operatively.